Ondansetron (Zofran)

Subscribe to Selected New Research on Ondansetron

1381 relevant articles (426 outcomes, 469 trials/studies) found for this Drug

Description: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Also Known As:

Zofran; SN 307; GR-38032F; GR38032F; Ondansetron Hydrochloride; Ondansetron Monohydrochloride; Ondansetron Monohydrochloride Dihydrate; Ondansetron, (+,-)-Isomer; Ondansetron, (R)-Isomer; Ondansetron, (S)-Isomer; SN-307; Dihydrate, Ondansetron Monohydrochloride; GR 38032F; Hydrochloride, Ondansetron; Monohydrochloride Dihydrate, Ondansetron; Monohydrochloride, Ondansetron; SN307; 4H-Carbazol-4-one, 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-

Relationship Network

Drug Context: Research Results

Heterocyclic Compounds: 23

1-Ring Heterocyclic Compounds

2-Ring Heterocyclic Compounds

3-Ring Heterocyclic Compounds

Carbazoles: 4

Ondansetron: 1381

1-hydroxyondansetron

Experts

1.	Gan, Tong J: 7 articles (05/2007 - 04/2002)
2.	Shende, D: 5 articles (09/2002 - 02/2000)
3.	Pellegrini, Joseph E: 4 articles (02/2007 - 04/2003)
4.	Sadhasivam, S: 4 articles (09/2002 - 02/2000)
5.	Madan, R: 4 articles (07/2001 - 02/2000)
6.	White, Paul F: 3 articles (12/2005 - 11/2002)
7.	Rosow, Carl E: 2 articles (05/2008 - 05/2008)
8.	Smith, Sarah E: 2 articles (05/2008 - 05/2008)
9.	Grecu, Loreta: 2 articles (05/2008 - 05/2008)
10.	Bittner, Edward A: 2 articles (05/2008 - 05/2008)

Related Diseases

1.	Vomiting 01/01/1999 - "However, there was a significant reduction in emesis management costs for patients treated after versus before the availability of ondansetron: for patients treated in the last third versus first third of the study period, there was a decrease in cost per patient per month of treatment of $374 (95% confidence interval, $243 to $505)" 03/01/1996 - "The need for antiemetic rescue therapy (ondansetron 0.15 mg/kg intravenously after three episodes of emesis prior to discharge) was significantly greater in children who received placebo compared with the ondansetron 0.15 mg/kg study group (13% vs 0%, P < 0.05)" 12/01/2001 - "The incidence of vomiting was significantly greater after infusion of placebo than after either low-dose or high-dose ondansetron" 12/01/1997 - "MEASUREMENTS AND MAIN RESULTS: All doses of ondansetron 0.05 mg/kg, 0.1 mg/kg, and 0.15 mg/kg were significantly more effective than placebo in reducing the incidence of emesis prior to, following discharge, and during the first 24 postoperative hours (p < 0.001)" 02/01/1997 - "RESULTS: During 0-24 h, the number of emetic episodes experienced was significantly greater (P = 0.048) with placebo (mean = 5) than ondansetron (mean = 2) and the proportion of patients experiencing no emesis was significantly greater (P = 0.039) with ondansetron (58%) than placebo (17%)" Order ALL the reference details at left...
2.	Postoperative Nausea and Vomiting (PONV) 01/01/1994 - "In conclusion ondansetron given preoperatively had proven to be an effective treatment for PONV after epidural block for lower abdominal surgery." 02/01/1994 - "Clearance has been received from the Food and Drug Administration for marketing of Zofran injection for the prevention of postoperative nausea and vomiting, at a dose of 4 mg IV over 2 to 5 min. Zofran has been evaluated in clinical studies with good results in the reduction or prevention of postoperative nausea and vomiting with minimal adverse reactions." 12/01/1999 - "IMPLICATIONS: We evaluated the antiemetic efficacy, safety, and routine use of prophylactic ondansetron, a "gold standard" antiemetic, in women undergoing radical breast surgery who were at a high risk of postoperative vomiting" 01/01/1999 - "Ondansetron, a selective serotonergic antagonist, is effective in reducing postoperative nausea and vomiting in several high-risk populations" 08/01/1996 - "Ondansetron, a selective serotonergic (5-HT3) antagonist, is effective in reducing postoperative vomiting in several high-risk populations" Order ALL the reference details at left...
3.	Nausea 03/01/2008 - "However, the latter improved nausea on day 2. A single 8 mg dose of ondansetron can maintain antiemetic efficacy in the majority of complete responders in arm A and arm B." 05/01/1994 - "RESULTS: The two schedules of ondansetron used in the first 24 hours were no different in their antiemetic efficacy, with similar rates for complete responses (76.7% v 72.0%, P = .472), complete plus major responses (90.2% v 82.0%, P = .135), and severity of nausea (P = .348)" 07/01/2001 - "There was a significant reduction in the frequency of emetic episodes and rescue antiemetic requirement in patients treated with ondansetron; however, ondansetron did not significantly reduce the incidence of nausea alone (14% in Group 2 vs 5% in Group 1, P = .065)" 06/01/1990 - "Ondansetron was also more effective in reducing acute nausea" 03/22/1990 - "Ondansetron was also more effective in controlling acute nausea, as assessed with a visual-analogue scale (P = 0.019) or a graded scale (P = 0.024)" Order ALL the reference details at left...
4.	Neoplasms (Cancer) 01/30/2006 - "Furthermore, the effects of ondansetron were significantly greater in cancer animals compared to shams" 03/01/2005 - "A prospective randomized trial of the antiemetic efficacy and cost-effectiveness of intravenous and orally disintegrating tablet of ondansetron in children with cancer." 12/01/1992 - "Priestman (Eur J Cancer Clin Oncol 25:529-533, 1989 [Suppl]) reported on a pilot and randomized study with ondansetron after single doses of 8 to 10 Gy to the upper abdomen" 12/01/1992 - "The safety of intravenous (IV) and oral ondansetron has been evaluated in over 7,000 cancer patients in world-wide clinical trials" 01/01/1992 - "Ondansetron was given as anti-emetic prophylaxis to 429 children receiving a variety of emetogenic cancer treatments for up to 8 days, in three, open, multicentre, European studies" Order ALL the reference details at left...
5.	Pruritus (Itching) 10/01/1998 - "Although under treatment with ondansetron a significant improvement of itching as assessed by the VAS score was demonstrated, this treatment was not preferred over placebo by the patients" 03/01/1999 - "We have evaluated the efficacy of ondansetron in the prevention of opioid-induced pruritus in a prospective, randomized, double-blind, placebo-controlled study" 06/01/2007 - "RESULTS: Ondansetron therapy was associated with ameliorations of pruritus that appeared to be clinically significant in 5 patients (38%); in these 5 patients the mean decrease in a subjective score of pruritus was 27% of the scale of the score" 02/01/2006 - "The role of ondansetron has been studied in preventing pruritus but the results have been contradictory" 01/01/2006 - "Ondansetron treatment in a child presenting with chronic intractable pruritus." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Metoclopramide (Reglan)
2.	Dexamethasone (Maxidex)
3.	Cisplatin (Platino)
4.	Droperidol
5.	Serotonin (5 Hydroxytryptamine)
6.	Granisetron (Kytril)
7.	Cyclophosphamide (Cytoxan)
8.	Ondansetron (Zofran)
9.	Antiemetics
10.	dolasetron mesylate (dolasetron)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Laparoscopic Cholecystectomy
3.	General Anesthesia
4.	Tonsillectomy
5.	Anesthesia

Best Treatments:
Research Summary Report
on Vomiting

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1231 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>